Frontiers in oncology · 2026
Targeting SRC to mediate solasonine's anti-cancer activity in hepatocellular carcinoma and its potential for multi-cancer therapy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Zheng, Xia Xiao Yang, Yang Jia Yao, Li Ke Nong, Hou Jun Lin
Аннотация
INTRODUCTION: Cancer remains a leading cause of mortality worldwide, with persistent therapeutic gaps across its heterogeneous subtypes. Solasonine, a steroidal glycoalkaloid from Solanum species, exhibits broad anti-tumor activity, yet its pan-cancer mechanisms of action remain poorly defined.
METHODS: A multi-tiered framework was employed: bibliometric analysis mapped the global research landscape; network pharmacology identified core solasonine-cancer target intersections, followed by GO and KEGG pathway enrichment and drug-target-pathway network construction; qRT-PCR, Western blotting, and CCK-8 assays in HCC cell lines experimentally validated the in silico-predicted hub target, SRC, and interrogated downstream signaling.
RESULTS: Bibliometric analysis showed solasonine research concentrated primarily on breast cancer, bladder cancer, and HCC. Network pharmacology identified eight core targets-SRC, EGFR, AKT1, CDH1, TNF, BCL2, ESR1, and STAT3-with SRC as the central network hub. Experimental validation confirmed solasonine suppressed SRC at both transcriptional and translational levels, and SRC overexpression significantly rescued solasonine-induced proliferative inhibition in HCC cells.
DISCUSSION: These integrated findings identify SRC as a critical mechanistic node mediating the pan-cancer anti-tumor effects of solasonine, particularly in HCC, and provide a rational foundation for its further development as a multi-target therapeutic agent.
METHODS: A multi-tiered framework was employed: bibliometric analysis mapped the global research landscape; network pharmacology identified core solasonine-cancer target intersections, followed by GO and KEGG pathway enrichment and drug-target-pathway network construction; qRT-PCR, Western blotting, and CCK-8 assays in HCC cell lines experimentally validated the in silico-predicted hub target, SRC, and interrogated downstream signaling.
RESULTS: Bibliometric analysis showed solasonine research concentrated primarily on breast cancer, bladder cancer, and HCC. Network pharmacology identified eight core targets-SRC, EGFR, AKT1, CDH1, TNF, BCL2, ESR1, and STAT3-with SRC as the central network hub. Experimental validation confirmed solasonine suppressed SRC at both transcriptional and translational levels, and SRC overexpression significantly rescued solasonine-induced proliferative inhibition in HCC cells.
DISCUSSION: These integrated findings identify SRC as a critical mechanistic node mediating the pan-cancer anti-tumor effects of solasonine, particularly in HCC, and provide a rational foundation for its further development as a multi-target therapeutic agent.